BOSTON -- (EUREKALERT!) -- Alexion Pharmaceuticals, Inc. today announced the first conference presentation of the topline Phase 3 data for ULTOMIRIS ® (ravulizumab), the first and only long-acting C5 ...
Ultomiris is a brand-name biologic medication prescribed for certain rare autoimmune disorders. Dosing of Ultomiris is done via intravenous (IV) infusions administered by a healthcare professional.
AstraZeneca (AZN) announced plans to seek accelerated approval for its rare disease therapy, Ultomiris, on Tuesday after the C5 complement inhibitor reached a key goal in a late-stage trial for ...
Ultomiris (ravulizumab-cwvz) is a prescription drug used to treat certain rare inflammatory conditions. Ultomiris can cause side effects that range from mild to serious. Examples include headache, ...
A year after nabbing FDA approval for its rare disease drug Ultomiris in generalized myasthenia gravis (gMG), AstraZeneca has launched the first TV ad for the therapy. For AstraZeneca, this ad is a ...
“It can take months, and sometimes years, to receive a correct diagnosis for PNH — a chronic, progressive and potentially life-threatening rare disease – which can be an overwhelming experience for ...
The FDA has issued a complete response letter (CRL) regarding AstraZeneca Plc's (NASDAQ:AZN) supplemental Biologics License Application seeking approval for long-acting C5 complement inhibitor ...
Ultomiris is administered intravenously by a healthcare professional, with infusion times varying from 24 to 90 minutes or more depending on the dose. The dosage of Ultomiris is determined by body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results